NEW YORK, NY -- (MARKET WIRE) -- March 01, 2007 -- Nephros, Inc. (AMEX: NEP) today reported that the Company has completed and submitted its response to the Food and Drug Administration (FDA) for the two informational requests related to the conditional approval of the Company’s Investigational Device Exemption (IDE) Application to begin a human clinical trial of the Company’s OLpur™ H2H™ Hemodiafiltration Module and OLpur™ MD 220 Hemodiafilter. The Company believes it has completed the regulatory filings required to commence its clinical trials in March. The Company also noted that it is in the final stages of gaining approval from one or more Institutional Review Boards (IRBs), the final step in the process before the commencement of its clinical trial.
